Frankfurt / Miami -- March 15, 2026
Record Investment Highlights Growing Transatlantic BioTech Interest
Crossover Consulting LLC today announced the successful completion of a $50 million investment round for a leading European biotechnology company. The round was led by two prominent US institutional investors with significant healthcare portfolios, marking one of the largest transatlantic biotech investment deals facilitated by the firm since its founding in 2012.
The investment will enable the European BioTech company to accelerate its clinical trials program, expand manufacturing capacity at its German facility, and establish a commercial presence in the United States. The deal represents a continuation of the growing trend of US institutional capital flowing into European life sciences companies, which Crossover Consulting has been at the forefront of facilitating.
"This transaction exemplifies the type of cross-border value creation that drives our mission," said the Managing Director of Crossover Consulting. "European biotech companies possess world-class science and innovation, while US institutional investors bring not only capital but also the commercial expertise and market access needed for global scale. Our role is to bridge these two ecosystems and create partnerships that accelerate breakthrough technologies."
A Growing Track Record in Life Sciences
The $50M investment marks Crossover Consulting's 12th successful life sciences transaction in the past three years, bringing the firm's total brokered capital in the healthcare and biotech sector to over $380M. The firm's dedicated Healthcare & BioTech practice, staffed with professionals holding advanced degrees in molecular biology, pharmaceutical sciences, and healthcare economics, has become a trusted advisor for European life sciences companies seeking US capital.
The transaction required extensive coordination across multiple jurisdictions, including compliance with both EU and US securities regulations, German foreign investment screening requirements, and FDA pre-submission strategy alignment. Crossover Consulting managed the complete investor outreach process, facilitated due diligence across three time zones, and negotiated terms that balanced the interests of existing European shareholders with the requirements of incoming US institutional investors.
About Crossover Consulting LLC
Crossover Consulting LLC is an international consulting firm specializing in connecting US and European markets. Founded in 2012 and headquartered in Frankfurt with a second office in Miami, the firm has served over 750 clients and brokered more than $2 billion in capital across 14 industries. Crossover Consulting provides market entry advisory, investor matching, cross-border M&A, and strategic consulting services to companies seeking transatlantic growth.